Drug Trial Radar · NCT00084136
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,571
Actual
Start
May 2005
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jun 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
Conditions
- HIV Infections
Interventions
AtazanavirDrug
400 mg taken orally daily
Didanosine (enteric-coated)Drug
400 mg taken orally daily
EfavirenzDrug
600 mg taken orally daily
EmtricitabineDrug
200 mg taken orally daily
Emtricitabine/Tenofovir disoproxil fumarateDrug
200 mg/300 mg taken orally once daily
Lamivudine/ZidovudineDrug
150 mg/300 mg taken orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Treatment Failure (PI Comparison)Time frame: Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up until ddI+FTC+ATV arm closed (May 22, 2008).
- Time to Treatment Failure (NRTI Comparison)Time frame: Virologic failure starting 14 weeks following randomization; disease progression starting 12 weeks following randomization; and death occurring at any time following randomization. Follow-up through study closure (May 31, 2010).
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
Harbor General/UCLA
Torrance, California
Univ. of Colorado Health Sciences Center, Denver
Denver, Colorado
Univ. of Hawaii at Manoa, Leahi Hosp.
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
Rush-Presbyterian/St. Lukes (Chicago)
Chicago, Illinois
Cook County Hospital Core Center
Chicago, Illinois
University of Minnesota
Minneapolis, Minnesota
Washington University (St. Louis)
St Louis, Missouri
HIV Prevention & Treatment CRS
HVTN 722 West 168th Street MSPH Bldg., New York
Beth Israel Medical Center
New York, New York
Cornell CRS
New York, New York
NY Univ. HIV/AIDS CRS
New York, New York
Community Health Network, Inc.
Rochester, New York
Univ. of Rochester ACTG CRS
Rochester, New York
University of North Carolina
Chapel Hill, North Carolina
Wake County Health and Human Services Clinical Research Site
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
The Ohio State Univ. AIDS CRS
Columbus, Ohio
Hosp. of the Univ. of Pennsylvania CRS
Philadelphia, Pennsylvania
Stanley Street Treatment and Resource
Providence, Rhode Island
The Miriam Hosp. ACTG CRS
Providence, Rhode Island
Vanderbilt Therapeutics CRS
Nashville, Tennessee
University of Texas, Southwestern Medical Center
Dallas, Texas
University of Texas, Galveston
Galveston, Texas
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Manguinhos, Rio de Janeiro, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Les Centres GHESKIO CRS
Bicentenaire, Port-au-Prince, Haiti
Dr. Kotnis Dispensary
Pune, India
YRG CARE Medical Ctr., VHS Chennai CRS
Rajiv Gandhi Salai Taramani, Chennai, India
NARI Pune CRS
Pune, Maharashtra, India
NARI Clinic at NIV CRS
Maharashtra State, Pune, India
College of Med. JHU CRS
P.O. Box 1131, Blantyre, Malawi
University of North Carolina Lilongwe CRS
Mzimba Road, Lilongwe, Malawi
Asociacion Civil Impacta Salud y Educacion - Miraf CRS
Barranco, Lima region, Peru
San Miguel CRS
San Miguel, Lima region, Peru
Wits HIV CRS
Johannesburg, Gauteng, South Africa
Durban Adult HIV CRS
Durban, KwaZulu-Natal, South Africa
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.